ArticleGynecologic oncology reports2026
Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of immune checkpoint inhibitors (ICI) has transformed the treatment of patients with advanced stage or recurrent mismatch repair deficient (dMMR) endometrial cancer. Importantly, however, ICI are commonly contraindicated in patients with preexisting autoimmune conditions. Immune related myasthenia gravis (irMG) is the second most common neurologic immune related adverse event (irAE) with ICIs, and there have been several case reports of ICI induced myasthenia gravis (MG) as well as cases of MG flares associated with ICI treatment. Case Presentation: This case report describes the successful use of pembrolizumab in combination with carboplatin and paclitaxel and then continued as maintenance in a 70-year-old patient with recurrent dMMR endometrial cancer and myasthenia gravis. Utilizing a multidisciplinary treatment team, the patient received plasmapheresis every 3 weeks, preceding pembrolizumab infusion, without clinical evidence of MG symptom flare. The patient remains in clinical remission 8 months following completion of maintenance therapy. Conclusion: Pembrolizumab was safely administered, without identifiable irAEs, and a robust clinical response in a patient with dMMR EC, where the clinical benefit of immunotherapy has been well established. Historically, patients with MG have been excluded from enrollment and treatment on clinical trials. Real world, pragmatic, clinical data may help inform expanded utilization beyond trial eligibility criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.